<DOC>
	<DOCNO>NCT00390624</DOCNO>
	<brief_summary>The purpose study combine Urodilatin ( ANP analogue ) , increase glomerular filtration rate ( GFR ) , mannitol , increase rate urinary flow solute excretion . We intend treat twenty consecutive allogeneic bone marrow transplant patient phase II study compare result historical control . We hypothesize incidence renal dysfunction , ARF thus mortality allogeneic bone marrow transplantation significantly reduce use protective agent Urodilatin mannitol . We feel combination best administer prior first two week treatment patient encounter immunosuppressive agent onset early transplantation complication .</brief_summary>
	<brief_title>Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin Mannitol</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Ularitide</mesh_term>
	<criteria>Age 1865 year Presence malignancy hematological disease whose treatment allogeneic stem cell transplant highdose condition therapy . Adequate baseline evaluation : adequate renal function ( creatinine clearance &gt; 60 ml/min ) ; Adequate hepatic function ( SGOT , SGPT , bilirubin alkaline phosphatase &lt; 1.5 time normal ) ; adequate cardiac function ( MUGA show leave ventricular ejection rest &gt; 45 % ) ; adequate pulmonary function ( DCLO &gt; 60 % ) . Known hypersensitivity ANP mannitol Congestive heart failure Previous bone marrow transplant BP le 90 mm systolic le 60 mm Hg diastolic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Urodilatin</keyword>
	<keyword>Mannitol</keyword>
	<keyword>Acute Kidney Failure</keyword>
</DOC>